Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B 99813. Oh WK, et al. Among authors: godley pa. Cancer. 2003 Dec 15;98(12):2592-8. doi: 10.1002/cncr.11829. Cancer. 2003. PMID: 14669278 Free article. Clinical Trial.
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.
Kornblith AB, Herndon JE 2nd, Zuckerman E, Godley PA, Savarese D, Vogelzang NJ; Cancer and Leukemia Group B (CALGB). Kornblith AB, et al. Among authors: godley pa. Ann Oncol. 2001 May;12(5):633-41. doi: 10.1023/a:1011102619058. Ann Oncol. 2001. PMID: 11432621 Free article. Clinical Trial.
Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA. Kim WY, et al. Among authors: godley pa. Urol Oncol. 2011 Nov-Dec;29(6):608-13. doi: 10.1016/j.urolonc.2009.09.012. Epub 2009 Dec 21. Urol Oncol. 2011. PMID: 20022268 Clinical Trial.
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.
Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Ballentine Carter H, Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P; American Society of Clinical Oncology Health Services Committee; American Urological Association Practice Guidelines Committee. Kramer BS, et al. Among authors: godley pa. J Clin Oncol. 2009 Mar 20;27(9):1502-16. doi: 10.1200/JCO.2008.16.9599. Epub 2009 Feb 24. J Clin Oncol. 2009. PMID: 19252137 Free PMC article. Review.
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.
Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK. Cowey CL, et al. Among authors: godley pa. J Clin Oncol. 2010 Mar 20;28(9):1502-7. doi: 10.1200/JCO.2009.24.7759. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159822 Free PMC article. Clinical Trial.
Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE. Chen RC, et al. Among authors: godley pa. BJU Int. 2012 Dec;110(11 Pt B):E721-6. doi: 10.1111/j.1464-410X.2012.11536.x. Epub 2012 Sep 27. BJU Int. 2012. PMID: 23016517 Clinical Trial.
108 results